Pharma Focus America

Tempus Expands Collaboration with AstraZeneca to Enhance Guideline-Directed Biomarker Testing in NSCLC Using Tempus Next

Monday, June 03, 2024

Tempus, a leader in artificial intelligence and precision medicine, has announced an expanded collaboration with AstraZeneca. This partnership utilizes Tempus Next to empower physicians with technology for guideline-directed biomarker testing in non-small cell lung cancer (NSCLC) patients. The constant updates to oncology guidelines pose challenges for their rapid integration into patient treatment plans. As part of their strategic collaboration, the two companies are scaling up a pilot program utilizing Next, Tempus’ care pathway intelligence platform. This program assists physicians in identifying NSCLC patients who could benefit from guideline-directed molecular testing, including screening for epidermal growth factor receptor (EGFR) mutations.

EGFR is a biomarker found in some NSCLC patients, with specific targeted therapies linked to it. Presently, around 30-40% of eligible NSCLC patients do not undergo appropriate testing. In September 2023, Tempus and AstraZeneca launched a pilot program leveraging Next to address this care gap at select provider sites. Through AI-driven analysis of unstructured clinical data, the program identifies eligible patients based on clinical guidelines and notifies treating physicians accordingly. The success of the pilot within the first six months has led to its expansion to encompass a total of 15 provider sites.

“Next was designed to ensure all patients have access to treatment plans based on the most up-to-date guidelines by equipping physicians with cutting-edge tools in their existing workflows to support the delivery of evidence-based care,” said Chris Scotto DiVetta, Senior Vice President, AI Applications at Tempus. “We were excited to see initial success in this program and look forward to contributing to a future where advanced technology and medical expertise unite to improve outcomes for all patients.”

Tempus Next is tailored to expedite the adoption of precision medicine and enhance patient outcomes. Integrating seamlessly with Electronic Medical Records (EMRs), the solution analyzes a comprehensive suite of data, including clinical notes, molecular information, and imaging, to pinpoint deviations from care guidelines. Participating health systems receive regular updates, supporting the implementation of guideline-directed care for their patients.

 

Source: businesswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024